Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the stock is above the 50 day and the 200 day with the trix ppo and macd all movin to the positive
Share structure her is crazy low
Share Structure
Market Value1 $21,980,673 a/o Nov 10, 2010
Shares Outstanding 68,689,603 a/o Aug 11, 2010
Float N/A
Authorized Shares 200,000,000 a/o Sep 21, 2010
Par Value 0.0010
Shareholders
Shareholders of Record 358 a/o Mar 31, 2009
Beneficial Shareholders N/A
wow I am really impressed with this play, the cahrt is oustanding
Debenture Press Release -----Applied Visual Sciences Announces Debenture Restructuring and Strategic Investor
http://finance.yahoo.com/news/Applied-Visual-Sciences-iw-522584474.html?x=0&.v=1
HERNDON, VA--(Marketwire - 10/19/10) - Applied Visual Sciences (OTC.BB:APVS - News) announced today that, on October 15, 2010, it entered into an agreement with the holders of the company's outstanding Series A 10% Senior Convertible Debentures due November 7, 2008, that extends the maturity date of the debentures, provides that the debentures will be non-interest bearing through the date of maturity, and for certain other amendments to the terms of the debentures and related agreements.
Under the terms of the agreement, the convertible debenture holders have agreed to extend the maturity of the notes to June 30, 2011. The debenture holders agreed to waive payment of approximately $638,163 of accrued but unpaid interest, late fees, mandatory default penalties totaling $2,496,149 and other amounts due under the debentures, in consideration of which the company agreed to issue an aggregate of 2,552,653 shares. Also, the debenture holders have agreed to waive prior breaches and defaults under the debentures and related debenture transaction documents and to release the company from related claims. The remaining principal amount of the amended debentures is $1,688,205 and will be non-interest bearing through the maturity date. Subject to the company's stock satisfying certain price and volume requirements, the holders have agreed to a provision permitting the company to force a conversion of the debentures. The holders have also agreed that the company is no longer required to register under the Securities Act the resale of the shares underlying their debentures and related warrants. Currently, the debentures are convertible at a price of $0.25. The agreement contains certain other amendments, representations and warranties of the parties and conditions to closing.
In addition, the company has been advised that, in March 2010, a strategic investor in the company, Dr. Joshua P. Prager, purchased approximately $838,205 in principal amount of the outstanding convertible debentures and certain related stock warrants from three of the original institutional investors in the company's 2006 debenture offering.
"This debenture restructuring is a major achievement for Applied Visual Sciences, and it comes at a critical time for the company," said Michael W. Trudnak, Chairman and CEO of Applied Visual Sciences. "With the recent corporate announcements and expectation of a transformational 2010 fourth quarter, it is imperative that Applied Visual Sciences maintains a strong financial profile. We appreciate the continued commitment from our legacy debenture holder and the additional commitment of our strategic investor."
In addition to this restructuring, the company has further reduced its outstanding liabilities through the equity conversion of outstanding notes payable and deferred executive salaries in the amounts of approximately $754,667 and $1,267,706, respectively. The total reduction in liabilities from all transactions is approximately $5,156,685, which represents an approximately 32% reduction from the liabilities balance reported for the quarter ended June 30, 2010.
The securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. For further information regarding the foregoing, please refer to the company's Form 8-K to be filed with the Securities and Exchange Commission and related exhibits.
Applied Visual Sciences, Inc.
Applied Visual Sciences, Inc., is the holding company and IT development organization for subsidiaries specializing in high-performance imaging analysis technologies and advanced analytics for automated recognition of targets of interest. Applied Visual Sciences' subsidiaries include Guardian Technologies International, Inc., a homeland security/defense technology entity, and Signature Mapping Medical Sciences, Inc., a healthcare technology entity. The company is quoted on the OTC Bulletin Board under the symbol APVS.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, capital raising activities, trends in the markets, variations in the company's cash flow, competition, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company's most recent filings with the Securities and Exchange Commission.
Guardian Technologies International Restructures, Changes Name to Applied Visual Sciences
Ticker Symbol Changes to APVS
HERNDON, VA, Jul 20, 2010 (MARKETWIRE via COMTEX) -- Guardian Technologies International, Inc.'s (OTCBB: GDTI) (OTCBB: APVS) Board of Directors has expanded the Company's organizational structure to better reflect its business operations and to provide an enhanced operational structure to capitalize on international business and joint product development opportunities. Guardian Technologies International, Inc. (GDTI) has been renamed Applied Visual Sciences, Inc. and is trading on the Over-the-Counter Bulletin Board under the new symbol APVS and new CUSIP number 038287108, effective July 19, 2010. APVS will be the parent holding company and IT development organization for the group.
GDTI has achieved certain significant corporate lifecycle milestones that necessitate a different corporate structure. The new structure will segregate distinct business operations into separate corporate entities, all under a single umbrella organization. The parent company, Applied Visual Sciences, will be the sole shareholder in two subsidiaries: Guardian Technologies -- the homeland security/defense technology entity and Signature Mapping Medical Sciences, Inc. -- the healthcare technology entity. APVS will maintain ownership of all existing and in-process patents, as well as any future patentable technology developed by its research and development staffs or developed as a tangential application of its core patented technologies. The subsidiaries will be the business operations focused on new product development, marketing, and sales for their respective markets.
The new structure will enable APVS to realize the following benefits:
-- Creation of autonomous business units with defined measurable goals
and objectives;
-- Alignment of risk characteristics to the specific product, line of
business or foreign market;
-- Provide a level of legal risk insulation to the core assets, the
patents & intellectual property;
-- Flexibility to maximize tax benefits, both domestic & foreign;
-- Flexibility and ease in negotiating and structuring mergers,
acquisitions, joint ventures, or joint development partnerships;
-- Facilitate the potential "spin-off" or sale of one of the subsidiary
entities;
-- Attract industry-specific investment.
The restructuring will be completed immediately as APVS is poised for strategic developments that include:
-- introduction of its tuberculosis diagnostics system, Signature Mapping
TBDx(TM), into the South African market,
-- commencing joint development with the Indian government of a
TBDx(TM) application specific to their market,
-- negotiations underway to form a joint venture for the development of a
suite of breast cancer detection applications, and
-- numerous domestic and international sales opportunities for Guardian's
PinPoint(TM) automated explosives and threat detection system.
Michael W. Trudnak, Chairman and CEO of Applied Visual Sciences, states, "As we transition from technology and product R&D to commercialization, we are putting the structure in place that will enable rapid revenue growth and expansion to advance the Company to the next level of corporate development. This new corporate structure provides the Board and management with total flexibility to maximize shareholder value."
Current shareholders may visit http://www.guardiantechintl.com/pdfs/QA_APVS_July2010.pdf for details on how the changes will affect their investment and for instructions relating to the new ticker symbol, APVS.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the markets, variations in the company's cash flow, competition, celebrity programs, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company's most recent filings with the Securities and Exchange Commission.
CONTACT:
For Applied Visual Sciences, Inc.:
Email Contact
+1 703-464-5495
Media:
Julie Shepherd
Accentuate PR
+1 815-479-1833
Email Contact
SOURCE: Applied Visual Sciences (formerly Guardian Technologies International)
CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=C28403BA226142FF
http://www2.marketwire.com/mw/emailprcntct?id=52E0D592511B091C
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Computers and Software:Software
Government:International
Travel and Hospitality:Airlines
Government:Security (law enforcement, homeland etc)
Medical and Healthcare:Healthcare
Government:National
Signature Mapping TBDx(TM) Demonstrates Positive Results
HERNDON, VA, Jun 21, 2010 (MARKETWIRE via COMTEX) -- Guardian Technologies International, Inc. (OTCBB: GDTI), today announced that testing of the fully automated tuberculosis (TB) detection system, Signature Mapping TBDx(TM) (SM TBDx), at the South African National Health Laboratories (NHLS) successfully validated the integrated performance of each hardware component of the automated slide management system. The integrated hardware-software TB detection solution accurately identified 100% of the TB slides processed during an abbreviated trial that was delayed due to shipping and customs issues beyond Guardian's control.
In scheduling the clinical trial Guardian was well aware of the tight timeframe, which afforded no margin of delay due to the fact that critical South African personnel were scheduled to attend a weeklong national TB conference at the conclusion of our scheduled time, as well as other logistical challenges associated with the World Cup Games. Based on SM TBDx's speed of diagnosis and strong performance, a consensus was reached by South Africa's top TB experts on a new strategy to expand the scope of the clinical trial protocols to more fully understand and empirically demonstrate the full potential of the new integrated technology. The intent is to measure and demonstrate an even greater level of routine production sensitivity that would translate into the detection of more TB scanty cases, a major area of missed diagnosis responsible for increased incidence of disease.
The urgency to complete the clinical trial of SM TBDx was further amplified by a newly announced aggressive HIV/TB population screening program of an additional 15 million citizens by June 2011, approximately 30% of the population of South Africa. To address the urgency of the situation and to avoid the potential delays of adhering to strict governmental procurement processes, decisions were reached to employ an alternative contracting vehicle to expedite deployment.
Dr. Gavin Churchyard, Chairman of The Aurum Institute, states, "Signature Mapping TBDx is an exciting new technology that enhances sputum smear microscopy for TB by combining automated slide management and computer detection of the TB bacillus. This technology breakthrough provides for the first time, the opportunity to more thoroughly analyze sputum smear samples to find TB, particularly in the earlier stages of disease when the number of bacilli present on the slide are fewer and may be missed with conventional microscopy. Finding and treating patients earlier will help reduce the spread of the disease, while automating the screening process will provide fast and consistent results. TBDx holds the promise to screen large numbers of TB suspects in a cost-effective manner, find more cases of TB and to reduce the TB burden in resource poor settings."
"As South Africa prepares to expand HIV and TB screening to an additional 15 million people, the urgency to complete the trial and negotiate a business contract is that much more vital. Collectively we have agreed to a contract framework to support a maximum rollout, in a minimum amount of time," commented Dr. Dave Clark, Deputy Chief Executive Officer of the Aurum Institute. "The keys to success are a government procurement vehicle that expedites the purchasing process, and securing a financial partner to fund the acquisition of the required hardware procurement. As Guardian's newly appointed Reseller/Distributor, we believe that both goals have been met and we expect to execute the financing agreements over the next two months."
The collective judgment of the interested parties was that the clinical trial protocols should be expanded beyond the current plan to include comparative data, as follows:
-- human expert readers under research conditions
-- human laboratory technologists reading under routine conditions
-- SM TBDx (at 100 fields of view per slide, the WHO accepted guidelines)
-- SM TBDx (500-1,000 fields of view per slide)
-- culture (considered the gold standard)
The rationale for expanding the trials to include 500-1,000 fields of view per slide was the ability to conduct a more thorough analysis of the sputum smear and the potential implications for higher sensitivity and more rapid TB detection and verification than the six to eight weeks required for culture. Such a study is only possible because of the speed with which SM TBDx can process and diagnose a sputum slide. Every effort will be made to keep the clinical trial moving expeditiously and to mitigate potential problems such as shipping and customs delays or access to replacement hardware inventories. The parties have agreed that the TBDx trial should be moved to the United States and be conducted under independent observer validation. The selection of the independent observer, the dates to recommence the trials, and the protocols are being coordinated by the Aurum Institute and NHLS to facilitate an unbiased comprehensive trial. It is anticipated that the recommencement will begin by July 19th.
"The new clinical protocols will establish higher standards of scientific credibility that will lead to greater international acceptance of SM TBDx. Further, when combined with the procurement and funding vehicles arranged by Aurum, the enhanced clinical trial should accelerate governmental approvals, drive increased revenue, and faster rollout throughout South Africa," stated Bill Donovan, Guardian's President. "The need for SM TBDx is present and growing. We intend to make a considerable positive impact on South African TB detection beginning in 2010."
For additional information about our activities in South Africa, please click on the following link: PDF - http://www.guardiantechintl.com/pdfs/Q_A_South Africa Press Release.pdf
Please click below to hear a radio interview with Dr. Dave Clark: Mp3 - http://www.guardiantechintl.com/multimedia/Aurum - June.mp3
About SM TBDx: In the first phase of clinical trials in Oct 2009, SM TBDx achieved 92% detection sensitivity and 3.75% false positive rate. The SM TBDx solution combines Guardian's highly sensitive and specific image analysis software with an automated slide loader capable of processing 200 slides without human intervention, a bar code reader, an automated microscope stage navigator to process the slide through the capture of 100 fields of view (FOV), and an auto-focus camera to digitally capture each FOV. SM TBDx Manages and synchronizes the hardware components for hands-free slide acquisition and TB detection analysis. A video of the TBDx automated solution is available at the following link:
Guardian Technologies to Begin Phase II Clinical Trials of Signature Mapping TBDx(TM) TB Diagnostics
HERNDON, VA and JOHANNESBURG, SOUTH AFRICA -- (Marketwire)
05/19/10
Guardian Technologies International, Inc. (OTCBB: GDTI) has returned to South Africa to complete the clinical evaluation of the Signature Mapping TBDx? (TBDx) integrated, fully automated slide management and TB detection solution. The clinical evaluation will be conducted in collaboration with the Aurum Institute for Health and under the supervision of the South Africa National Health Laboratory Services (NHLS) -- TB Program. It is expected that preliminary results will be available prior to month's end. However, fully documented results and analysis reports will take several additional weeks.
While accurate detection remains the most critical component of any tuberculosis diagnostic solution, it alone cannot address the magnitude of the worldwide TB pandemic. South Africa and other highly burdened countries must find a solution to the secondary challenge of the growing volume of sample slides compounded by limited highly skilled technical and financial resources.
"Guardian's TBDx solution addresses these challenges by providing the first-of-its-kind fully automated slide management and TB detection system capable of screening large volumes of stained sputum slides without human intervention," stated Rich Borrelli, Guardian's Healthcare Vice President. "Guardian's research and development teams have accomplished this groundbreaking product without sacrificing the 92% detection sensitivity and 3.75% false positive rate experienced in the Phase I clinical trial."
The TBDx solution combines Guardian's highly sensitive and specific image analysis software with an automated slide loader capable of processing 200 slides without human intervention, a bar code reader, an automated microscope stage navigator to process the slide through the capture of 100 fields of view (FOV), and an auto-focus camera to digitally capture each FOV. Guardian has developed the software code to manage and synchronize the hardware components for hands-free slide acquisition and TB detection analysis. To view a video of the TBDx automated solution, please click on the following link
Guardian Technologies Receives 1st Automated Tuberculosis Detection System Order From South Africa
HERNDON, VA, Apr 20, 2010 (MARKETWIRE via COMTEX) -- Guardian Technologies International, Inc. (OTCBB: GDTI) has received its first order for three fully automated Signature Mapping Tuberculosis Diagnostic (TBDx(TM)) systems for planned shipment at the end of April. The order is in preparation for the final clinical evaluation of the TBDx fully automated detection system that will begin in May 2010.
"Guardian Technologies is extremely proud to deliver to the South African National Health Laboratory Services ("NHLS") the first total tuberculosis diagnostic solution that addresses the dual challenges of detection and slide throughput," states Rich Borrelli, Guardian's Vice President of Healthcare. "Testing of the automated TBDx system to date indicates that it provides a fast, accurate diagnosis at a low cost without requiring clean rooms, cultures or other resource intensive processes. Successful completion of the final clinical evaluation in South Africa will set the stage for the introduction of the fully automated system to other countries faced with large, growing volumes of TB such as India, China, and Russia."
The breakthrough TBDx system combines automated digital image analysis software to detect TB in sputum microscopy samples using a fully automated slide handling system capable of continuously processing 200 slides without the need for human intervention. The complete automated system will provide the NHLS with the ability to eliminate tedious and time-consuming diagnostic efforts while more consistently and accurately detecting tuberculosis bacilli and maintaining a low false positive rate.
The final clinical evaluation has two objectives: (i) confirm the initial clinical results obtained in October 2009 utilizing the auto-focus integrated microscope and camera capability, and (ii) measure the operational efficiencies and potential cost-savings of fully automated operations. The measurement of slide analysis throughput is required for NHLS to determine the quantity of required systems and deployment strategy. Post-clinical evaluation, the three TBDx systems will be transitioned to NHLS laboratories most heavily involved in ongoing tuberculosis research.
About Guardian Technologies International: Guardian Technologies uses high-performance imaging technologies and advanced analytics to create integrated information management products and services. Currently, the company offers products and services for use in disease detection and airport security. By automating the processing of large quantities of graphic, numeric, and textual data, Guardian allows organizations to more efficiently detect, extract, analyze or effectively act upon the information. Guardian's solutions are designed to improve the quality and speed of decision-making and enhance organizational productivity and accuracy. Founded in 2003, Guardian is publicly traded on Nasdaq as GDTI.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the markets, variations in the company's cash flow, competition, celebrity programs, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company's most recent filings with the Securities and Exchange Commission.
CONTACT:
For Guardian: Richard Borrelli +1 703-464-5495
Julie Shepherd of Accentuate PR, +1-815-479-1833, Email Contact
SOURCE: Guardian Technologies International, Inc.
CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=5D7AC82882F1D786
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Computers and Software:Software
Pharmaceuticals and Biotech:Trials
Medical and Healthcare:Healthcare
Pretty cool. Hit my scanner.
Guardian Technologies Delivering World's First Fully Automated Tuberculosis Detection System
Integrated Software and Hardware System Addresses Challenges in Diagnostic Accuracy and Increases Lab Productivity While Lowering Costs
HERNDON, VA, Apr 08, 2010 (MARKETWIRE via COMTEX) -- Guardian Technologies International, Inc. (OTCBB: GDTI) today announced that it has joined forces with two prominent industry leaders in laboratory solutions, Prior Scientific (www.prior.com) and Olympus Soft Imaging (www.soft-imaging.net), to create and accelerate the integration of Guardian's Signature Mapping(TM) (SM TBDx(TM)) diagnostic software into a first-of-its-kind, fully automated sputum microscopy solution for the computer-aided-detection of tuberculosis.
A Memorandum of Understanding (MOU) between Guardian, The Aurum Institute for Health Research (Aurum), and the South African National Health Laboratory Services (NHLS) established the objectives and product specifications to address the diagnostic challenges faced in South Africa. Conceptually, the MOU established a pathway to deployment of SM TBDx focused on retrofitting existing microscopes with digital cameras.
SM TBDx's 92.86% accuracy in positive cases and 3.75% false positive field of views, in the November 2009 clinical trials, far exceeded the NHLS program objectives of 80% accuracy and no more than 20% false positives, as well as industry norms of less than 70% accuracy.
SM TBDx's exceptional performance prompted a request by NHLS to additionally address the growing challenge of sputum slide processing and diagnostic throughput, an ever increasing challenge in South Africa and the other 21 countries with high burdens of TB. Worldwide estimates indicate 100 to 150 million slides are processed and analyzed by laboratory technologists annually with volumes growing at estimated double digit rates per annum.
The fully integrated SM TBDx system to be delivered initially to South Africa, and then beyond, will be capable of 24/7 slide processing that will require little human intervention while maintaining highly accurate diagnostic results. An additional benefit of this system will be that highly skilled laboratory personnel will be able to focus more attention on the most difficult cases, rather than reviewing every slide.
"For decades, the world has needed a more accurate, low cost, fast TB diagnostic solution -- particularly one that can accurately diagnose early stage TB and TB in HIV-positive patients -- in centralized laboratories and at the point of care. Guardian's Signature Mapping TBDx is the answer," said Rich Borrelli, VP of Business Development for Guardian's Health Division. "The product offerings of the SM TBDx fully automated and manual retrofit systems position Guardian to address the full range of diagnostic environments. Furthermore, SM TBDx's advanced image analysis integrated with automation positions Guardian to immediately address the worldwide crisis in TB detection."
The enhanced requirement of NHLS for the fully automated diagnostic solution delayed the Phase 2 (final) clinical trial in S. Africa to later this month. This scheduled delay is necessary to fully oblige the requirement for the automation integration, as well as planned commercialization and rollout of the system to South Africa's 240 laboratories upon successful completion of the trial.
Guardian is currently in negotiations for the sale and deployment of the initial three systems in South Africa that would be used in support of the Government's Recheck Program and to support tuberculosis research at the Department of Microbiology, NHLS, at the University of Pretoria. Guardian expects to soon announce a distribution/reseller agreement with a South African healthcare company for SM TBDx distribution in Africa, within South America, Indonesia, and Australia.
The fully automated slide management and detection system has major implications for TB programs in heavily burdened countries like India, Russia and China, which handle extremely large and growing volumes of slides. As part of Guardian's international marketing strategy, SM TBDx is being modified to address a different staining method and microscope lighting source as used in most of the world. Indian health officials have directly communicated an interest in a fully automated TB detection system to handle its estimated 35-40 million slides per year.
To further penetrate the world TB diagnostic market, Guardian's SM TBDx product offerings will be expanded to provide diagnostic solutions at large centralized laboratories or hospitals (fully automated system), smaller local laboratories in rural areas (retrofit system), and mobile labs to provide 100% screening of the population in the most remote of areas.
About Guardian Technologies International: Guardian Technologies uses high-performance imaging technologies and advanced analytics to create integrated information management products and services. Currently, the company offers products and services for use in disease detection and airport security. By automating the processing of large quantities of graphic, numeric, and textual data, Guardian allows organizations to more efficiently detect, extract, analyze or effectively act upon the information. Guardian's solutions are designed to improve the quality and speed of decision-making and enhance organizational productivity and accuracy. Founded in 2003, Guardian is publicly traded on Nasdaq as GDTI.
About Prior Scientific: Prior Scientific is the leading manufacturer of high precision motorized microscope stages, automated slide loading systems, laser autofocus systems, fluorescence illumination systems, motorized filter wheels, custom optical systems and a wide array of microscopy accessories for a variety of applications. Prior Scientific's dedication to customer service has positioned Prior as a trusted supplier for the industrial, scientific, educational and OEM markets. Prior Scientific excels in the creation of OEM prototypes, custom-built products, and complete system solutions according to individual customer requirements for any optical, focusing or positioning application. For over 90 years, Prior has been delivering high quality and precision products.
About Olympus Soft Imaging Solutions: As the leading system solution provider in microscopy, Olympus puts all of its expertise and passion into developing forward-looking products. The Olympus global strategy is oriented towards enhancing effectiveness and value creation in its business areas. This drive for excellence has motivated Olympus to form a dedicated company: Olympus Soft Imaging Solutions. The company operates as a part of the global framework of Olympus Micro Imaging. It is positioned as a global supply unit for micro imaging software and hardware system development, production, distribution, support and service within the Olympus Group -- for all applications. This guarantees superior quality, the most innovative and user-friendly solutions and product flexibility in the field of microscopy and imaging.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the markets, variations in the company's cash flow, competition, celebrity programs, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company's most recent filings with the Securities and Exchange Commission.
CONTACT:
For Guardian
Business Development: Richard Borrelli +1-703-464-5495
Media: Julie Shepherd, Accentuate PR, +1-815-479-1833, Email Contact
SOURCE: Guardian Technologies International, Inc.
CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=1581F2A5B0CFC5BD
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Computers and Software:Hardware
Computers and Software:Peripherals
Pharmaceuticals and Biotech:Trials
Medical and Healthcare:Medical Devices
Medical and Healthcare:Surgery and Treatments
Computers and Software:Software
World TB Day Is March 24, 2010 -- Why Should You Care?
HERNDON, VA, Feb 04, 2010 (MARKETWIRE via COMTEX) -- Guardian Technologies International (OTCBB: GDTI) -- The world observes World Tuberculosis Day on March 24, 2010, with the campaign theme of, "On the Move Against Tuberculosis: Innovate to Accelerate Action."
WHY SHOULD YOU CARE about a disease that's been considered virtually extinct in the U.S. since antibiotics to treat it came on the scene in the 1940s?
BECAUSE:
-- One third of the world's total population is infected with tuberculosis (TB). One in 10 of these individuals will become sick with active TB in their lifetime, according to World Health Organization (WHO) statistics.
-- Approximately 8.8 million people contract TB each year -- a new infection every second.
-- Nearly 2 million people die from the disease annually.
-- Infected individuals generally infect 10-12 people before they are positively diagnosed.
-- With the fluidity of international travel, this is not just a developing nations' problem anymore. It is virtually impossible to control the entry of TB patients into the country.
-- In 2009, the United States reported its first case of a medically resistant TB -- a highly contagious, aggressive, drug-resistant form of tuberculosis.
-- U.S.-based Guardian Technologies, in close collaboration with S. Africa's government health agencies, has developed a new automated TB diagnostics method that is faster, cheaper and more accurate, to meet the specific needs of countries that bear the highest burdens of TB. The new Signature Mapping TBDx(TM) holds the potential to save millions of lives and dollars.
-- "We are all connected by the air we breathe, and that is why this must be everyone's problem." -- Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention (Associated Press http://apnews.myway.com/article/20091227/D9CRLR680.html, 12/27/09).
Need more reasons? Ask us.
Experts from Guardian Technologies International (OTCBB: GDTI) in Herndon, VA and South Africa's Aurum Institute are available to discuss the worldwide TB pandemic and how new technology is enabling earlier detection, and making diagnosis faster, more accurate and less expensive to help slow the spread of this deadly disease.
Visuals available: Photos and video of TB testing and slides of TB sputum samples.
About Guardian Technologies International:
Guardian Technologies uses high-performance imaging technologies and advanced analytics to create integrated information management products and services. Currently, the company offers products and services for use in disease detection and airport security. By automating the processing of large quantities of graphic, numeric, and textual data, Guardian allows organizations to more efficiently detect, extract, analyze or effectively act upon the information. www.guardiantechintl.com
CONTACT:
Julie Shepherd
Accentuate PR
+1-815-479-1833
SOURCE: Guardian Technologies International, Inc.
CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=3599D48998102DA7
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Computers and Software:Software
Medical and Healthcare:Healthcare
Government:International
Guardian Technologies International Issues Annual Letter to Shareholders
HERNDON, VA, Jan 27, 2010 (MARKETWIRE via COMTEX) -- Guardian Technologies International (OTCBB: GDTI) has issued its annual letter to shareholders:
Dear Shareholder,
Looking back on 2009 -- it was a tumultuous year of challenges, a year of increased product applications and business opportunities, both domestically and internationally, and a year in which we accomplished significant platforms for growth. While the stock market has yet to realize the enormous economic value of our core technology, the international healthcare community has openly and actively embraced our Signature Mapping(TM) platform, specifically our automated tuberculosis detection product, Signature Mapping TBDx. In addition, I am extremely pleased with the direction the Transportation Security Administration has taken with the DICOS Initiative, which we co-chair. The imaging standards proposed under DICOS would allow for seamless integration of PinPoint(TM) across all manufacturers and all scanning platforms.
During 2009, we made critical decisions intended to position Guardian as the global leader in both healthcare diagnostics and security screening. I'm proud of the accomplishments being reported to you, as well as the resolve the organization displayed in confronting the challenges and moving the company closer to success in this uncertain economy.
HEALTHCARE
In healthcare, our focus in 2009 was primarily on the detection of tuberculosis. Guardian went to extreme measures to meet objectives that many established, world-renowned individuals and companies have failed to achieve. Our achievements:
-- Completed the development of Signature Mapping TBDx(TM) (SM TBDx(TM)), our automated TB detection software in August 2009 -- a full three months ahead of schedule;
-- Successfully completed a SM TBDx Phase I clinical trial under the supervision of the South Africa government, in December 2009. The trial exceeded all criteria and we are confident that Phase II (the final phase), scheduled for early 2010, will go equally well. On the strength of the performance of SM TBDx, we feel our company is positioned to quickly capture a significant share of this billion dollar plus market.
-- Delivered the SM TBDx proposal requested by India's government healthcare agencies in December. It accommodates the Indian laboratory protocols and provides for a fully automated diagnostic system, from automated slide handling to image capture to case level analysis. India's senior government healthcare officials and scientists requested a proposal to fund the migration of SM TBDx to the Indian standard for sputum microscopy after our meetings with them in October and November.
We are happy to report that our efforts in the fight against the global TB pandemic are beginning to be recognized internationally. In addition to the very successful discussions with South African and Indian health officials, news outlets in Johannesburg have recently published an informative, positive report on Guardian's TBDx product. The article states, "With its combination of sensitive diagnostic technology and labour-saving automation, TBDx could revolutionize TB testing in high burden countries like South Africa..." The article is available online at: http://www.plusnews.org/Report.aspx?ReportId=87607.
SECURITY
In security, our focus in 2009 was primarily on shifting the existing security paradigm from a proprietary hardware focus to a more integrable solution incorporating PinPoint software. In addition, we established Guardian as an expert in security. We have effectively staked our position by demonstrating a definitive understanding of the complexities and risks of security, while offering the fundamental missing element that bridges the security gap -- the identification of threats by the use of automated detection software that is consistent versus the current ineffective methodology. Our accomplishments:
-- Joined NEMA's Digital Communication in Security (DICOS) standards
initiative in August 2009. Funded by the TSA and the Department of
Homeland Security, the committee is tasked with developing digital imaging
and communications standards that can be used, in future government
procurements, to enable networking between scanning systems and
standardization of the imaging output from the hardware so third-party
software and components, like PinPoint, can more easily be developed,
tested and deployed. As co-chair of the DICOS working committee, Guardian
led the drafting of the proposed standards which, will impact acceptance of
third-party software on scanners used by TSA and DHS.
-- Participated in a funded proof-of-concept testing for the detection
of specific liquid explosives for a major international government security
organization. Due to government non-disclosure requirements, we cannot
disclose details of the testing, but we can assure you that Guardian's
PinPoint(TM) threat identification software exceeded the government's
performance expectations and outperformed every other participant in the
project. Guardian anticipates that governmental funding will be made
available for the development of a complete PinPoint(TM) liquids detection
module in early 2010.
-- Submitted requested proposals to several international governments
after successfully demonstrating PinPoint to them for specific high-
security programs and events. Guardian expects to receive responses and/or
take next steps in 2010.
Facing Challenges
Without discounting in any way the progress made in 2009 and the accomplishments in product and business development, there is no doubt 2009 was a challenging year. I recognize and acknowledge that, as shareholders, you are concerned about the depressed share price. So am I. The negative impact of the depressed share price has greatly restricted our ability to raise the capital needed for operations and development efforts. The accomplishments of 2009 occurred through the sheer force of will of our employees as there has been very little cash on hand -- a situation that limits staff expansion and the development of additional product applications. I can assure you that we are doing everything within our control to mitigate the financing constraints, provide a stable financial situation, and increase shareholder value.
An example of the limitations imposed by inadequate working capital is mammography. During 2009 controversy swirled around whether women under 50 should have mammograms. The question arises as a result of the prevalence of false positives leading to unnecessary biopsies, a situation which clearly highlights the need for accurate image analysis and data extraction technologies like Guardian's Signature Mapping platform. Although there is a very significant opportunity in mammography, we are unable to provide the financial resources to fund the additional development needed to complete this application. Instead, we focus our resources on monetizing our tuberculosis diagnosis application, since we believe that represents very near-term revenue.
To create media visibility and reach potential customers and the financial community, we have retained the services of Accentuate PR, a firm that previously helped us garner coverage on CNN/Anderson Cooper and other international media outlets. These efforts promoted Guardian in a way that attracted new investors and helped to maintain a stable share price that more realistically reflected the true economic value of the technology and future revenue potential. Additionally, we've ramped up fundraising efforts with an aggressive schedule of meetings with potential investors and funds, concurrent with accelerating new business development efforts on multiple fronts. We are making headway and expect to continue our progress throughout 2010.
As a result of increased global economic uncertainty in 2009, customers lengthened their decision-making cycles and put off making key purchasing decisions, which caused shortfalls in our projections. In addition, we became a victim of our own success. With the exceptional results obtained by SM TBDx in the initial clinical trial, the TB executives in South Africa have made a strategic decision to leapfrog current hardware technology and to focus on a next-generation hardware configuration that doesn't currently exist for TB detection. While we are disappointed about the delay associated with this decision, we have not lost sight of the fact that Guardian will secure its position as the technology leader in not only the automated microscopic detection of tuberculosis, but in automated laboratory detection systems. We believe strongly in Guardian's potential and are committed to realizing that opportunity.
Going Forward
The company is very well positioned to execute its long-term vision and strategy. Broad-based successes will demonstrate that the company's industry-leading technologies will increasingly capture the attention of decision makers worldwide. Further, the solid foundation we built in 2009 as a clear leader in digital image analysis and data extraction puts us in a position of strength as we enter 2010. Guardian's evolved structure and growing interest of major multinational customers allows our specialized teams to extend their reach and penetrate new markets with renewed vigor and motivation.
Given the recent Christmas Day bombing attempt, President Obama has called for new security screening technologies. Although the majority of the attention has been focused on full-body scanners as THE solution, they DO NOT possess explosives detection capabilities (the ability to identify an explosive vs simply providing an image that may or may not contain an explosive). Guardian is using this opportunity to meet with government and non-government influencers and decision makers, as well as the investment community, to demonstrate that Guardian's PinPoint explosives and weapon detection capabilities are unmatched by current scanners and are a necessary addition for airport and facilities checkpoint security screening.
We have contacted Senator Lieberman, Chairman of the Senate Homeland Security Committee, and members of the Senate and House Homeland Security Committees. We have requested individual meetings with these members and have asked to testify in upcoming Homeland Security hearings about software solutions that solve the underlying problems in scanner threat detection.
REQUESTING YOUR ASSISTANCE
We are requesting that you contact your Congressional Representatives and ask them to make a change. Let them know that it is in the public's best interest to improve current security screening technology by looking beyond hardware to existing software technologies, like Guardian's PinPoint. Ask that they consider integration of imaging analysis software and components that will close the gap in security. We have developed sample letters that we encourage you to personalize and send to your specific elected officials since they are charged with looking out for you -- their constituents. The letters and links providing contact info for your specific congressional representatives are located at http://www.guardiantechintl.com/writetocongress.
In conclusion, we are renewing our commitment to building shareholder value through intelligent growth in 2010 as we focus on generating revenue and leveraging the exciting progress that Guardian made in 2009. I want to thank you, our shareholders, employees and partners, for your continuing support during 2009 and for playing an important role in the continued development of our products.
Sincerely,
Michael W. Trudnak
Chief Executive Officer
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the markets, variations in the company's cash flow, competition, celebrity programs, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company's most recent filings with the Securities and Exchange Commission.
CONTACT:
Julie Shepherd
Accentuate PR
+1-815-479-1833
Email Contact
SOURCE: Guardian Technologies International, Inc.
CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=332766294019C89C
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Computers and Software:Hardware
Computers and Software:Software
Travel and Hospitality:Airlines
Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Trials
Government:Security (law enforcement, homeland etc)
This thing is going to run big Tuesday and all week IMO.
The United Nations just picked up on this company.
http://www.unpan.org/PublicAdministrationNews/tabid/113/mctl/ArticleView/ModuleID/1460/articleId/20854/default.aspx
Where is everyone!!! GDTI up 50% in the last couple weeks!!!
5 filings today popped up. 4 insiders buying 125000 common stock and 8-k form with some bank. They cant sell the shares until it reachs 3 bucks.
Wierd, maybe this thing will pop up again.
dont quite know what to think of these guys anymore but todays run up is grand
We have broken through the squeeze area of the shorts. Hopefully we can see an upward trend from here.
"Funding usually occurs some time in the time frame of February or March of that following year."
Source: http://www.secinfo.com/d1968u.u1m.d.htm
Hopefully we'll hear something soon about this $12 million grant...
Invitation
I invite all of you to join me at the new TRBI Transferorbit board.
I think we will get a run of pr's next week followed by the 12 mill goverment grant.should see some contracts signed real soon
.
One cannot look at the trading pattern this past week. There are those out there that will use any stock they have a loss in to have a tax loss. The real happening will start around Jan 7th when all the new Years hoopla is behind us all and it is back to the old grind.
UBSS and NITE have been buying ALLOT of stocks thees last two weeks. Someone is understanding how cheap it is now...
Can go to last trading day of the year.
I think that is the reason too, and also that some stop losses have been triggered. Anyways, isn't this the last week for the tax-loss selling?
We are at years end. Everyone is presently taking there end of year losses. I expect to see more till the end of the year.
Does anyone know why this thing is going down so much to come out shortley. We should be going the other direction in my opinion..
IT was going to be announced in the middle of Janurary.I sure hope they get the 12 mil they talked about...
Anyone remembers when the grant they spoke about in the last conference call, was being announced? Wasn't it in late November or beginning of December?
Anyone know why there appears to be no trading activity so far today?
There is several things for this stock that should be coming out very soon.Hopefully we will here this coming week.My personal oppinion is this thing is really going to take off.
Let's hope we get some good news from management on Friday. Would even be better if the news had a revenue stream somewhere inbedded within it.
Guardian Technologies International, Inc. (GDTI) SqueezeTrigger Price is $1.44
Monday November 26, 8:30 am ET
Approximately 2.8 Million Shares Shorted Since December 2005 According to Buyins.net Research Report
HERNDON, Va.--(BUSINESS WIRE)--Guardian Technologies International, Inc. (OTCBB:GDTI), innovators of groundbreaking threat detection technology with critical and immediate applications for the homeland security and healthcare markets, today announced that BUYINS.NET, www.buyins.net, is initiating coverage of Guardian Technologies International after releasing the latest short sale data to November 2007. From December 2005 to November 2007 approximately 36.4 million total aggregate shares of GDTI have traded for a total dollar value of nearly $52.6 million. The total aggregate number of shares shorted in this time period is approximately 2.8 million shares. The GDTI SqueezeTrigger price of $1.44 is the volume weighted average short price of all short selling in GDTI. The first of several short squeezes is expected to begin when shares of GDTI close above $0.73, where approximately 127,000 shares have been shorted. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.
Month Total Vol.
Short Vol.
Avg. Price Short $ Value
December '05 1,893,373
145,790
$2.70 $393,268
January '06 626,222 48,219 $2.39 $115,123
February 918,208 70,702 $2.49 $176,048
March 827,090 63,686 $2.40 $152,846
April 1,305,700 100,539 $2.01 $201,580
May 1,029,147 79,244 $1.90 $150,762
June 946,634 72,891 $1.82 $132,844
July 2,085,966 160,619 $1.79 $287,107
August 4,271,560 328,910 $2.02 $663,576
September 843,125 64,921 $1.92 $124,485
October 1,081,047 83,241 $1.52 $126,526
November 1,760,102 135,528 $1.13 $153,146
December 1,754,323 135,083 $0.88 $118,198
January '07 1,494,137 115,049 $0.94 $107,858
February 1,122,496 86,432 $1.07 $92,266
March 1,379,390 106,213 $1.02 $108,603
April 773,924 59,592 $1.05 $62,274
May 1,246,170 95,955 $0.86 $82,761
June 1,493,670 115,013 $0.82 $94,023
July 4,663,496 359,089 $1.15 $411,157
August 1,022,488 78,732 $0.87 $68,103
September 980,382 75,489 $0.76 $57,183
October 1,239,493 95,441 $0.78 $74,205
November 1,656,556 127,555 $0.73 $93,587
Total:
36,414,699
2,803,932
$1.44
$4,047,530
*short volume is approximated using a proprietary algorithm.
**average short price is calculated using a volume weighted average short price.
***short volume is the total short trade volume and does not account for covers.
Guardian Technologies International, Inc. has been on the OTCBB Naked Short Threshold list for 5 trading days and short sellers have been failing to deliver for 10 trading days. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. SEC Regulation SHO, under the Securities Exchange Act of 1934, mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.
About Guardian Technologies International
The impact of Guardian’s industry-first computer aided detection technologies are immediate and profound for helping to eliminate human error in both the Homeland Security and the Medical Industry sectors. The Company’s software solutions can be seamlessly installed to complement existing imaging devices, such as baggage scanners and medical MRI, to scan the contents of any image and immediately identify items of interest not easily discernable by the human eye.
* Airport Security: Guardian’s technology complements and enhances current-generation baggage x-ray scanners with the ability to automatically and effectively detect, locate, and identify explosives and other types of threats.
* Disease Identification: Existing medical imaging devices used in Computer Aided Detection (CAD) are further improved with Guardian’s auto-diagnostic ability to detect anomalous tissue (e.g., tumors) and other potential disease states or conditions.
* Technology-Independence: Because Guardian’s technologies utilize and process the actual image output generated by the original imaging systems, virtually any existing or future imaging device can be upgraded with Guardian’s products, delivering an instant, multi-billion dollar potential customer base with no competition.
Guardian’s technology and product development partnerships include a Cooperative Research and Development Agreement (CRDA) with the U.S. Department of Homeland Security - Science and Technology Directorate. The Company’s platform and product suite is protected by a robust patent portfolio. They are also ramping up new technologies and plan to acquire complementary technologies to accelerate the Company’s high-growth business model.
INVESTOR CENTER
INVESTOR-SPECIFIC INFORMATION
CURRENT STOCK QUOTES AND HEADLINES
INVESTOR FACT SHEET
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 1,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month’s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Guardian Technologies International, Inc. has paid $995 per month to purchase data for information provided in twelve monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact:
Guardian Technologies International, Inc.
Michael W. Trudnak, 703-464-5495
info@guardiantechintl.com
or
Trilogy Capital Partners
Ryon Harms, 800-592-6067
Investor Relations
info@trilogy-capital.com
Source: Guardian Technologies International, Inc.
Guardian Announces High-Profile Spanish Law Enforcement Authorities to Host Final Real World Scenario Test on November 28-29 in Madrid
Monday November 26, 10:15 am ET
Company Returns to Spain with Upgraded PinPoint Product Able to Identify Specific Threats Identified by Spain and European Union as Gravest Threats
HERNDON, Va.--(BUSINESS WIRE)--Guardian Technologies International, Inc. (OTCBB:GDTI), innovators of groundbreaking threat detection technology with critical and immediate applications for the homeland security and healthcare markets, has announced a scheduled pivotal final test involving highly-volatile explosives in Madrid sponsored by TEDAX. TEDAX is the elite Spanish government agency, a part of the Civil Guard, charged with safeguarding people and property against terrorist activity. High-ranking Spanish government and security officials are expected to attend along with leading security contractors interested in commercializing PinPoint in Spain and throughout the entire European Union.
Guardian recently completed the data collection phase of this initiative and is now returning to Spain with a significantly enhanced PinPoint product that incorporates the ability to accurately detect a range of explosive compounds that have been identified by security agencies in Spain and the rest of the European Union as among the gravest threats.
The next phase of the TEDAX initiative, scheduled for November 28-29, 2007, represents the latest progress in a series of successful performance enhancements of Guardian’s unique and proprietary PinPoint™ technology. The final test also follows an operational concept test and demonstration that took place earlier this year at Barajas International Airport in Madrid.
Last month, Guardian collected thousands of x-ray images that were used to develop unique signatures for each new explosive compound by processing the images through PinPoint’s proprietary supervised artificial intelligence platform. These new signatures were used to update PinPoint’s threat assessment database.
“We are very pleased to announce that in a relatively short period of time we have upgraded PinPoint to detect the specific threats facing Spain and other European nations,” said Bill Donovan, President and Chief Operating Officer of Guardian Technologies International. “We believe this adaptability is perhaps one of the most impressive aspects of our proprietary technology. We are honored to be invited by TEDAX to showcase PinPoint’s next generation capabilities to some of the highest ranking government officials in Spain.”
Guardian’s PinPoint product line uses breakthrough technology designed to significantly improve the performance of x-ray screening devices by providing security personnel vastly improved abilities to identify explosives, drugs and other threats.
Guardian recently signed a milestone agreement with International Threat Detection Systems (ITDS), an industry-leading distributor and integrator of a comprehensive line of x-ray security and metal detection solutions. ITDS offers an extensive distribution network that includes the Prosegur Group, a high-profile security firm that employs three out of five security employees in Spanish airports.
This final test will also be used as the platform to introduce PinPoint’s capabilities throughout the remainder of Europe. Passenger traffic in Spain’s 47 airports is growing at nearly 10% per year and may reach the 200 million passenger mark within a year. Portugal’s passenger traffic growth rate at their 12 main airports is similar to Spain’s and has precipitated the need for substantial airport expansion to meet the demand.
Initially designed for the concerns of aviation security, PinPoint™ will improve screener efficiency, reduce unnecessary traveler delays, and provide airport ownership with a return on their technology investment. Additionally, the software can be used for building security and train stations that are rapidly becoming a major security concern around the world.
Guardian’s PinPoint platform and product suite is protected by a robust patent portfolio. The Company is developing new technologies and plans to acquire complimentary technologies to accelerate their high-growth business model.
To watch an informative investor video detailing Guardian’s PinPoint technology and to learn more about the Company’s high-growth business model, please visit http://www.trilogy-capital.com/tcp/guardian.
About Guardian Technologies International
The impact of Guardian’s industry-first computer aided detection technologies are immediate and profound for helping to eliminate human error in both the Homeland Security and the Medical Industry sectors. The Company’s software solutions can be seamlessly installed to compliment existing imaging devices, such as baggage scanners and medical MRI, to scan the contents of any image and immediately identify items of interest not easily discernable by the human eye.
* Airport Security: Guardian’s technology complements and enhances current-generation baggage x-ray scanners with the ability to automatically and effectively detect, locate, and identify explosives and other types of threats.
* Disease Identification: Existing medical imaging devices used in Computer Aided Detection (CAD) are further improved with Guardian’s auto-diagnostic ability to detect anomalous tissue (e.g., tumors) and other potential disease states or conditions.
* Technology-Independence: Because Guardian’s technologies utilize and process the actual image output generated by the original imaging systems, virtually any existing or future imaging device can be upgraded with Guardian’s products, delivering an instant, multi-billion dollar potential customer base with no competition.
Guardian’s technology and product development partnerships include a Cooperative Research and Development Agreement (CRDA) with the U.S. Department of Homeland Security - Science and Technology Directorate. The Company’s platform and product suite is protected by a robust patent portfolio. They are also ramping up new technologies and plan to acquire complimentary technologies to accelerate the Company’s high-growth business model.
For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/guardian.
To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/guardian/quote.html.
To view an investor fact sheet about the company, visit http://www.trilogy-capital.com/tcp/guardian/factsheet.html.
Contact:
Guardian Technologies International, Inc.
Michael W. Trudnak, 703-464-5495
info@guardiantechintl.com
or
Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com
Source: Guardian Technologies International, Inc.
they are not shorts , they are debenture holders from previous financings . They have stock and options they were given for their loans . They sell the stock to retrieve their initial investment and then they FREE RIDE the options . I believe that they have to be in the 70's to break even on their stock .
REVENUE WILL HEAL ALL
TonyP
havent been following this one the last couple days...but just looked now...no volume n the last trade was .61 ...n the bid is .65...so ya the shorts may be done.....looks dead thou...GLTA
are the shorts about done
GDTI $ 0.70
Guardian Technologies International Inc. -0.08
Shares Short 429,400
Days to Cover (Short Ratio) 8.4
Short % of Float 1.85 %
Shares Short - Prior 410,700
Short % Increase / Decrease 4.55 %
Squeeze RankingTM -5
Nov 15, 2007 on the reg sho list.....have to cover within 13 trading days...look for a couple more big shakes..then should go right back up...GLTA
BUYINS.NET: TLEO, VVTV, GDTI, GSPG, MACM, MSGI Have Also Been Added To Naked Short List Today
Nov 16, 2007 (M2 PRESSWIRE via COMTEX)
If you liked it at .76 you should love it at .67
I wish I had some more powder I would load the boat AGAIN
NOTHING HAS CHANGED I am down BIG-MONEY
BUT I AM STILL A BUYER
TonyP
what the F--- happened why the drop was getting ready to load up. bought 2500 at 76. now what???
It was beautiful my daughter was watching the VIEW and Whoopi was talking about airport security and how they couldn't tell Mothers Milk from a liquid bomb . I ran upstairs and E-MAILED Whoopi and the view about GDTI .
Might do some good , might not . All it takes one to the right people and we get fresh eyes .
TonyP
I hope that we have a very successful RSNA show in Chicago after Thanksgiving . GDTI will be presenting themselves and their new partner Rogan Delft will also be talking about GDTI . I have been in this stock for a long time but I have never seen this much opportunity on the table . We have to get more people on this board and then start E-MAILING to get even more eyes on the company . We also have to ask the company for updates on some of the older PR'S ,like RUSSIA . I currently E-MAIL 3 newspapers and several funds . We need more eyes on GDTI.
REVENUES = $$$$$
TonyP
Guardian Announces Release of Letter to Shareholders to Spotlight Recent Strategic Achievements
Wednesday November 14, 6:30 am ET
President Highlights Distribution and Development Partnerships with Industry Leaders AutoClear, ITDS, India-Based Hi-Tec, Rogan Delft and the Aurum Institute
HERNDON, Va.--(BUSINESS WIRE)--Guardian Technologies International, Inc. (OTCBB:GDTI), innovators of groundbreaking threat detection technology with critical and immediate applications for the homeland security and healthcare markets, today announced that President and Chief Operating Officer Bill Donovan has released an official Letter to Shareholders to update investors on the Company’s major news announcements in recent weeks.
“An essential component of my job as President is to ensure that our current and potential shareholders have a comprehensive understanding and a clear perspective of our various achievements and activities,” said Mr. Donovan. “I invite all interested parties to read this letter to gain a better understanding of Guardian’s recent milestones and our vision for the future.”
Begin Letter
Fellow Investor,
You are a valued shareholder during one of the most exciting periods of growth in Guardian’s history. One of the strategies employed by Guardian is to keep our direct costs at a minimum by utilizing well positioned distribution channels to access market opportunities for our technology products. Within the last two weeks, we announced four key new partnership agreements with some of the world’s foremost leaders in both the homeland security and healthcare industries. Each of these distribution partnerships represents a milestone achievement for Guardian as we move towards commercializing our innovative, next-generation imaging technology.
This month, we announced two major distribution agreements with International Threat Detection Systems (ITDS) and Hi-Tec Aviation Safety & Security Systems (Hi-Tec) that extend Guardian’s international distribution footprint in Europe, India and Latin America. These powerful distribution partners provide access to high-ranking aviation security and government officials in each of these multibillion-dollar markets.
As you may know, Guardian continues to make significant progress in Spain. In fact, we recently completed a live explosive data collection initiative hosted by TEDAX, the elite government agency charged with safeguarding people and property against terrorist activity in Spain. In anticipation of Spanish government final approval for PinPoint™, we intend to leverage our partnership with ITDS to open near-term revenue opportunities in Spain and Portugal. Furthermore, ITDS recently entered a key reseller and systems integration agreement with Madrid-based Prosegur Group. Prosegur is one of the world’s most trusted security companies, employing three out of every five security employees in Spain’s airports and 100% of the employees in Portugal’s airports.
While Europe represents one of the world’s largest markets for our products, Guardian is also looking towards India as a vital and potentially lucrative region. Our exclusive distribution agreement with Hi-Tec is a vital step forward in that direction as we move to capitalize on the projected $20 billion budget to update India’s largest airports, including Mumbai, New Delhi, Bangalore, Kolkata and Chennai.
Our distribution agreements with IDTS and Hi-Tec will be integral to the relationship of another major partner announced last week--AutoClear. AutoClear not only offers a formidable distribution network reaching nearly every region around the world, but they will be the first to integrate our innovative image analysis technologies into their comprehensive line of security x-ray scanners. Our relationship with AutoClear enables us to meet the increasing demand for a fully integrated hardware and software solution that distributors like Terralink, ITDS and Hi-Tec have been asking for.
Additionally, our healthcare division signed a landmark joint development agreement with the Aurum Institute, the leading international research institute committed to the detection and treatment of HIV, malaria and TB. Together, we will develop a fully automated imaging analysis system for the early identification of tuberculosis and malaria. That agreement led to the signing of a strategic relationship with Rogan Delft to fully integrate the technology developed between Guardian and Aurum into the Delft Odelca-DR™ digital x-ray system (more than 30,000 have already been deployed). Combining these strategic relationships position Guardian on the forefront of disease detection for developing countries around the world.
Guardian is also making significant progress here in the U.S., where we recently signed a landmark extension of our Cooperative Research and Development Agreement (CRDA) with the Federal Transportation Security Laboratory (TSL). TSL is a branch of the U.S. Department of Homeland Security and is located within the Federal Aviation Administration’s (FAA) William J. Hughes Technical Center. We are very excited about this extension as it provides further validation of PinPoint’s progress towards crucial TSA approval.
We are more committed than ever to the commercialization of our products and continue to receive almost daily validation about just how far-reaching our revenue and earnings opportunities are in both the healthcare industry and the homeland security sector. Everybody at Guardian is enthusiastic about the future of our company and fully understands that there is still much work to be done.
I would like to take this opportunity to thank all of our current shareholders for their ongoing support. Delivering shareholder value remains paramount to our mission.
Thank you for your time and continued interest.
Sincerely,
Bill Donovan
President and Chief Operating Officer
Guardian Technologies International
End Letter
Contact:
Guardian Technologies International, Inc.
Michael W. Trudnak, 703-464-5495
info@guardiantechintl.com
or
Investor Relations
Trilogy Capital Partners
Ryon Harms, 800-592-6067
info@trilogy-capital.com
Source: Guardian Technologies International, Inc.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
312
|
Created
|
12/08/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |